Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi Sells 1,827 Shares

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 1,827 shares of Phreesia stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $27.46, for a total value of $50,169.42. Following the sale, the chief financial officer now directly owns 103,591 shares in the company, valued at approximately $2,844,608.86. The trade was a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, February 18th, Balaji Gandhi sold 5,771 shares of Phreesia stock. The shares were sold at an average price of $30.04, for a total value of $173,360.84.
• On Thursday, February 13th, Balaji Gandhi sold 28,759 shares of Phreesia stock. The shares were sold at an average price of $30.00, for a total value of $862,770.00.
• On Monday, January 27th, Balaji Gandhi sold 4,813 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total transaction of $132,261.24.
• On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The stock was sold at an average price of $27.31, for a total transaction of $159,135.37.
• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total transaction of $22,555.28.
• On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total value of $85,018.95.

Phreesia Stock Performance

Shares of PHR opened at $26.00 on Friday. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $30.53. The firm has a market capitalization of $1.53 billion, a PE ratio of -17.69 and a beta of 1.03. The firm has a 50-day moving average price of $27.38 and a 200 day moving average price of $24.18. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Johnson Financial Group Inc. boosted its stake in Phreesia by 381.3% during the 4th quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock valued at $28,000 after purchasing an additional 896 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Phreesia in the fourth quarter valued at $30,000. BankPlus Trust Department bought a new position in Phreesia during the fourth quarter valued at about $34,000. Quarry LP grew its holdings in Phreesia by 210.9% during the fourth quarter. Quarry LP now owns 2,835 shares of the company’s stock worth $71,000 after acquiring an additional 1,923 shares during the period. Finally, Venturi Wealth Management LLC acquired a new stake in Phreesia in the 4th quarter valued at about $76,000. 92.10% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

PHR has been the topic of a number of research analyst reports. Citigroup increased their target price on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 price objective on shares of Phreesia in a report on Tuesday, December 10th. KeyCorp raised their price target on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th. Canaccord Genuity Group lifted their price target on shares of Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, March 13th. Finally, Piper Sandler reiterated an “overweight” rating and set a $33.00 price objective (up previously from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Phreesia presently has an average rating of “Buy” and a consensus price target of $31.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.